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Increased Release of Tumor Necrosis Factor-a 
Into the Cerebrospinal Fluid and Peripheral 
Circulation of Aged Rats 
Anna-Leena Sin~n, MD, PhD; Yong Liu, MD; Giora Feuerstein, MD; and lohn M. Hallenbeck, MD 
Background and Purpose: We earlier reported that risk factors for stroke prepare brain stem tissue for 
a modified Shwartzman reaction, incIuding the development of ischemia and hemorrhage and the 
production of tumor necrosis factor-a, after a provocative dose of lipopolysaccharide. In the present 
study, we sought to determine whether blood and central nervous system cells of rats with the stroke risk 
factor of advanced age produce more proinflammatory and prothrombotic media tors than do those of 
young rats of the same strain. 
Methods: Levels of tumor necrosis factor-a and platelet activating factor in the cerebrospinal fluid and 
tumor necrosis factor-a in the serum of 2-year-old and 16-week-old Sprague-Dawley rats were monitored 
before and after challenge with lipopolysaccharide. 
Results: No consistent tumor necrosis factor-a activity was found in the cerebrospinal fluid or blood of 
control animals. Intravenous administration of lipopolysaccharide (1.8 mg/kg) increased serum tumor 
necrosis factor-a levels but had no effect on tumor necrosis factor-a in the cerebrospinal fluid. Serum 
tumor necrosis factor-a increased much more in aged rats than in young rats. When lipopolysaccharide 
was injected intracerebroventricularly, tumor necrosis factor-a activity in cerebrospinal fluid increased 
significantly more in old rats than in young rats. Baseline levels of platelet activating factor in 
cerebrospinal fluid were significantly higher in old rats than in young rats, and the levels increased to a 
greater degree in aged rats on stimulation. 
Conclusions: Rats with the stroke risk factor of advanced age respond to lipopolysaccharide with a more 
exuberant production of tumor necrosis factor-a and platelet activating factor than young rats of the same 
strain. These findings are consistent with our working hypothesis that perivascular cells are capable of 
exaggerated signaling of endothelium through cytokines such as tumor necrosis factor-a in animals with 
stroke risk factors. The effect of such signaling might be to prepare the endothelium of the local vascular 
segment for thrombosis or hemorrhage in accord with the local Shwartzman reaction paradigm. (Stroke 
1993;24:880-888) 
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R isk factors for stroke, such as aging, hyperten-sion, diabetes, and atherosclerosis, are associ-ated with increased subendothelial accumula-
tion of monocytes and macrophages,1,2 Expression of 
the macrophage-derived cytokines tumor necrosis fac-
tor-a (TNF-a) and monocyte chemoattractant protein-l 
has been demonstrated in human atheromas.3- 5 
See Editorial Comment, page 887 
We have been interested in the possibility that an 
inter action of perivascular macrophages with endothe-
lium could contribute to the increased risk of stroke in 
hypertension and in advanced age. This interaction 
could be mediated by increased activity of cytokines 
such as TNF-a and interleukin-l (IL-l), which are able 
to increase endothelial adhesion of monocytes, increase 
procoagulant properties, and suppress anticoagulant 
properties of the endothelium and circulating blood 
elements.6- S The altered state of blood vessels induced 
by stroke risk factors could ren der such vessels locally 
vulnerable to thrombosis or hemorrhage in response to 
transient activation of intravascular coagulation or of 
complement. The site of thrombus formation would be 
determined by the preexisting vessel disturbance and 
not by the intravascular process activating the comple-
ment or coagulation systems, thereby following the local 
Shwartzman re action paradigm.6- S In an earlier study, 
we found that several risk factors for stroke, including 
advanced age, diabetes, hypertension, and genetic 
stroke-proneness, prepared brain stern tissue for a 
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modified Shwartzman re action that involved the devel-
opment of ischemia and hemorrhage after a provocative 
dose of lipopolysaccharide administered intracisternaIly 
or intravenously.9 Furthermore, when chaIlenged with a 
provocative intravenous dose of lipopolysaccharide, rats 
with hypertension produced more TNF-a in their blood 
than did normotensive rats. 1O,1l Hypertensive rats also 
synthesized and released more TNF-a from brain tissue 
after the injection of lipopolysaccharide into the lateral 
cerebral ventric1e than did normotensive rats. 1O,1l To 
determine whether the increased release of inflamma-
tory media tors is associated with stroke risk factors 
other than high blood pressure, we measured the pro-
duction of TNF-a and platelet activating factor (P AF), 
two proinflammatory and procoagulant media tors, in 
the blood and cerebrospinal fluid (CSF) of aged com-
pared with young normotensive rats. TNF-a was chosen 
to represent the cytokine c1ass of media tors because it 
activates endothelium for leukocyte adherence and pro-
coagulant processes. 6 P AF was selected to represent the 
lipid inflammatory mediators, which induce leukocyte 
chemotaxis and adhesion and activate prothrombotic 
processes.12 These variables were measured in the se-
rum and CSF under basal and stimulated conditions, 
with lipopolysaccharide administered intravenously or 
injected into the lateral cerebral ventric1e. Lipopolysac-
charide was chosen as the stimulus for the release of 
TNF-a and P AF because it is a potent activator of ceIls 
capable of producing cytokines or PAF.6,12,13 
Materials and Methods 
Two-year-old (23-24-month-old) and 16-week-old 
male Sprague-Dawley rats were purchased from Zivic-
Miller (Zelienople, Pa.) and housed at 22°C with a 
12-hour/12-hour light/dark cyc1e, with food and tap 
water ad libitum. The mean±SEM body weight was 
858±21 g for the 2-year-old rats (n=36) and 550±16 g 
for the 16-week-old rats (n=36). The difference in body 
weight between the groups was significant (p<O.OOl, 
Student's two-tailed t test). 
These experiments were conducted according to the 
principles set forth in the Guide for the Care and Use of 
Laboratory Animals, Institute of Laboratory Animal 
Resources, National Research Council (US Depart-
ment of Health, Education, and Welfare publication 
No. [NIH] 85-23, 1985). 
Surgical Procedures 
The rats were anesthetized with halothane (4% in 
100% oxygen). For intravenous injections, a sterile 
PE-50 catheter was inserted into the femoral vein under 
aseptic conditions. Lipopolysaccharide from Escherichia 
eoli serotype 0111: B4 (phenol extracted; Sigma Chem-
ical Co., St. Louis, Mo.) dissolved in sterile, pyrogen-
free 0.9% NaCI was injected through the catheter. 
Lipopolysaccharide was administered at three dose lev-
els, 1 JLg/kg, 1.8 mg/kg, and 3.6 mg/kg, to reflect its 
effect at a threshold dose and at a dose that maximaIly 
activates TNF-a in rats,l°,11,14 After the injection, the 
catheter was puIled out and the vein ligated. For 
intracerebroventricular injections, the rat was placed in 
a stereotaxic device (David Kopf Instruments, Tujunga, 
Calif.). A midline cut was made on the scalp to expose 
the parieto-occipital bone area, and the musc1es at-
tached to the occiput were gently separated to expose 
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the atlanto-occipital membrane. A stainless-steel guide 
cannula was placed on the parietal skuIl (coordinates 
from bregma: anteroposterior, 0.8 mm; lateral, 1.2 mm) 
and fixed with glue. Lipopolysaccharide dissolved in 
sterile, pyrogen-free 0.9% NaCI was injected in a total 
volume of 10 JLL by me ans of a premeasured 30-gauge 
cannula (7.5 mm) over aperiod of 5 minutes. An 
additional 2 minutes were aIlowed for dispersal of the 
injected fluid before withdrawal of the cannula. Because 
differences in brain volume do not correlate with differ-
ences in body weight in adult rats,15 the intracerebro-
ventricular doses of lipopolysaccharide were calculated 
per rat rather than per body weight. The three doses 
used (750 ng per rat, 1.35 mg per rat, and 3.0 mg per rat) 
corresponded to the intravenous doses of lipopolysac-
charide calculated for a body weight of 700 g. Control 
rats received 10 JLL of sterile, pyrogen-free 0.9% NaCI 
through an intracerebroventricular needle. 
Two hours after the injection of saline or lipopolysac-
charide, the rats were anesthetized with halothane and 
placed in a stereotaxic device. A sterile 30-gauge ne edle 
attached to a sterile syringe was inserted into the 
intracisternal space through the atlanto-occipital mem-
brane. Clear CSF in a volume of 150 JLL was withdrawn 
and frozen immediately in a sterile Eppendorf viaIon 
dry ice. Thereafter, a laparotomy was performed, and a 
sterile 23-gauge butterfly needle was inserted into the 
abdominal aorta and blood was withdrawn into a sterile 
syringe. A 2-mL volume of the coIlected blood was 
aIlowed to c1ot, and serum was coIlected. 
Tumor Necrosis Factor Assay 
The serum or CSF sampIes were stored at 20°C for 
1-2 weeks until assayed for TNF-a using the L-929 ceIl 
lysis bioassay, as described elsewhere.16 In brief, L-929 
ceIls were grown in supplemented Eagle's minimum 
essential medium (MEM) + 10% fetal bovine serum 
(FBS) in 150-mL tissue culture flasks; 8x 105 ceIls wero 
seeded into 50 mL of medium. L-929 ceIls were plated 
at 4x 105 ceIls/mL in a 100-JLL weIl and incubated 
overnight. Before the experiment, the medium was 
aspirated, and 50 JLL of MEM + 10% FBS was added to 
the weIl. Test sampIes (25 JLL of serum or CSF) 
underwent twofold serial dilutions by sequential trans-
fer of 50 JLL across the weIls. In addition, 50 JLL of 
actinomycin D was added to each weIl to a final 
concentration of 0.4 JLg per weIl. Incubation was termi-
nated by aspiration of the supernatants and washing 
with normal saline (200 JLL per weIl). 
After aspiration of the saline, the ceIls were stained 
by exposure to 50 JLL of 0.05% crystal violet in 20% 
ethanol for 10 minutes. Scoring of the weIls was done 
visuaIly, and TNF-a units were calculated as the recip-
rocal of the highest dilution giving 50% lysis of a weIl. 
To convert to units per milliliter, this value was multi-
plied by 20. 
Platelet Activating Factor Assay 
A 100 -JLL aliquot of CSF was used for the P AF 
radioimmunoassay using a commercial PAF-radioim-
munoassay kit (NEK-062, Dupont/NEN Products, Bos-
ton, Mass.). The sensitivity of the assay was 50 pg. 
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White Blood Cell Counts 
In a parallel study, rats (10 in each group) were 
anesthetized with halothane (4% in 100% oxygen). 
When surgical anesthesia was reached (usually within 
3-5 minutes), a laparotomywas performed and a sterile 
23-gauge butterfly ne edle was inserted into the abdom-
inal aorta. A blood sampie (1 mL) was then withdrawn 
into a heparinized sterile syringe. The blood sampies 
were collected in the morning before 10 AM. The total 
leukocyte count of the freshly withdrawn blood was 
measured with an automatic cell counter (System 9000, 
Baker Instruments). The differential leukocyte counts 
for neutrophils, monocytes, and lymphocytes were made 
from a blood smear stained with Giemsa-Wright's stain. 
Measurement of Arterial Pressure and Heart Rate 
In parallel experiments, rats (four in each group) 
were anesthetized with halothane, and a sterile PE-50 
catheter was implanted into the left femoral artery for 
continuous monitoring of blood pressure and sampling 
of arterial blood. The catheters were tunneled under 
the back skin, exited at the nape of the neck, and 
secured by a soft spring wire. After the rats had 
recovered from anesthesia, the arterial catheter was 
connected to apressure transducer (Narco Bio-Systems 
RP 1500i, Houston, Tx.), and blood pressure and heart 
rate were continuously recorded on the Narcotrace 80 
computerized physiograph (Narco) and sampled auto-
matically every 30-60 seconds by a Northstar-Hazeltine 
computer for 30 minutes. Thereafter, a blood sampie (1 
mL) was withdrawn from the femoral artery for analysis 
of blood glucose. A single dose of lipopolysaccharide 
(1.8 mg/kg) was injected into the femoral arte rial cath-
eter, and the catheter was then reconnected to the 
pressure transducer and blood pressure monitored for 
an additional 3 hours. A second blood sampie (1 mL) 
for blood glucose measurement was withdrawn 2 hours 
after lipopolysaccharide administration. The rats were 
then killed by injecting an overdose of pentobarbital 
into the femoral arterial catheter. Blood glucose was 
analyzed using routine methods. 
Statistical Analysis 
The dose-response relations were analyzed by two-
way analysis of variance (ANOVA) using the css/pc 
statistical package for microcomputers (Complete Sta-
tistical System, StatSoft Inc., Tulsa, Okla.). When 
ANOV A revealed significances in the test parameters, 
Tukey's test was used to analyze the differences be-
tween individual treatment groups. 
Results 
TNF-a activity in the CSF or serum of control animals 
was low or absent. The 1.8- and 3.6-mg/kg i.v. doses of 
lipopolysaccharide increased serum TNF-a levels in a 
dose-dependent manner, but the low dose of 1 }.Lg/kg had 
no effect; the increase in serum TNF-a activity was 
greater in old rats than in young rats (Figure 1, top 
panel). Time-course studies at the 1.8-mg/kg dose con-
firmed the previous findings ll,14 that the peak response in 
serum TNF-a activity is reached 2 hours after lipopoly-
saccharide administration. Thus, the serum TNF-a level 
in young rats 2 hours after lipopolysaccharide adminis-






















• 2-YEARS OLD 
o 16-WEEKS OLD 
SALINE 0.001 1.8 3.6 
SALINE 0.001 1.8 3.6 
LPS (mg/kg) 
FIGURE 1. Bar graphs show dose-response eifect of intra-
venous lipopolysaccharide (LPS) on serum (top panel) and 
cerebrospinal fluid (CSF) (bottom panel) tumor necrosis 
factor (TNF)-a in 2-year-old and 16-week-old rats. Values 
(mean±SEM) represent levels of TNF-a 2 hours after injec-
tion of saline or LPS. n=5-8 in each group. *p<O.05 
(Tukey's test) compared with 16-week-old rats; +p<O.05 
(Tukey's test) compared with saline-treated group. 
declined to 12.8±9.4x 103 units/mL at 3 hours after 
lipopolysaccharide administration. In the old rats the 
corresponding values were 114.3±33.6x 103 units/mL and 
33.3 ± 16.4x 103 units/mL, respectively. The 3.6-mg/kg Lv. 
dose of lipopolysaccharide increased the CSF levels of 
TNF-a in the aged rats, whereas the lower doses had no 
effect (Figure 1, bottom panel). 
With the intracerebroventricular injection of lipo-
polysaccharide, TNF-a activity was increased in serum 
and CSF after the 1.35- and 3.0-mg per rat doses, 
whereas the low dose of 750 ng per rat had only minimal 
or no effect; at the highest dose the increase in serum 
TNF-a activity was significantly greater in old rats than 
in young rats (Figure 2, top panel). After intracerebro-
ventricular administration, the 1.35- and 3.0-mg per rat 
doses of lipopolysaccharide increased TNF-a activity in 
the CSF in a dose-dependent manner in the aged rats 
(Figure 2, bottom panel). The peak response in TNF-a 
activity in the CSF in the young rats was achieved at the 
1.35-mg per rat dose. At both dose levels the increase in 
CSF TNF-a activity was greater in the aged than the 
young rats (Figure 2, bottom panel). 
The effect of lipopolysaccharide on the level of PAF 





































• 2-YEARS OL[) 
o 16-WEEKS OLO 
SALINE 0.00075 1.35 3.0 
LPS (mg/rat) 
FIGURE 2. Bar graphs show dose-response effect o[ intra-
cerebroventricular (ICV) lipopolysaccharide (LPS) on serum 
(top panel) and cerebrospinal fluid (CSF) (bottom panel) 
tumor necrosis factor (TNF)-a in 2-year-old and 16-week-old 
rats. Values (mean±SEM) represent levels of TNF-a 2 hours 
after injection of saline or LPS. n=5-8 in each group. 
*p<O.05 (Tukey's test) compared with 16-week-old rats; 
+p<O.05 (Tukey's test) compared with saline-treated group. 
level of P AF was higher in the old rats than in the young 
rats. Intravenously administered lipopolysaccharide had 
no effect on P AF release into CSF. With the intracere-
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broventricular injection of lipopolysaccharide, the CSF 
level of P AF increased significantly after the dose of 
1.35 mg per rat in the old rats, whereas in the young rats 
the CSF P AF levels did not change significantly after 
either dose. 
In parallel studies, the white blood cell counts in 
untreated old and young rats ranged from 3 x 103 to 
10 X 103 cellsl pL The mean white cell count in the old 
rats was 5.7±O.8x 103 and in the young rats 4.7±O.8x 103 
cellsl p,L. The percentages of neutrophils, lymphocytes, 
and monocytes in blood of old rats (n = 10) were 27 ±4% 
(mean±SEM), 64±4%, and 6±2%, respectively. The 
corresponding cell counts in the young rats (n=9) were 
11±4%, 84±4%, and 3±1 %, respectively. The total 
white blood cell counts or the monocyte counts were not 
significantly different in old rats compared with young 
rats. However, the old rats' blood contained significantly 
fewer lymphocytes (p<O.Ol, Student's two-tailed test 
for independent sampies) and significantly more neu-
trophils (p<O.05, Student's two-tailed t test) than the 
blood of young rats. 
The mean arterial pressure, heart rate, and serum 
glucose levels were measured in six rats. No significant 
differences were found in the hemodynamic variables or 
the serum glucose levels between the young and old 
rats. The mean arterial pressure and he art rate before 
administration of lipopolysaccharide were 104±4 
mm Hg and 302±28 beats per minute, respectively, in 
the 16-week-old rats. The corresponding values in the 
2-year-old rats were 106±8 mm Hg and 323±29 beats 
per minute, respectively. At 2 hours after an intravenous 
bolus of 1.8 mg/kg lipopolysaccharide, the blood pres-
sure and he art rate were 108±2 mm Hg and 319±15 
beats per minute in young rats and 103±2 mm Hg and 
367±24 beats per minute in old rats. The nonfasting 
serum glucose in young rats was 299±20 mg/dL 
(mean±SEM, n=3) and in old rats was 313±35 mg/dL 
(n=3). 
Discussion 
Sprague-Dawley rats with the stroke risk factor of 
advanced age produced more TNF-a in blood and CSF 
in response to a provocative dose of lipopolysaccharide 
TADLE 1. Effect oe Lipopolysaccharide on Cerebrospinal Fluid Platelet Activating Factor Level in 2-Year-Old and 16-Week-Old Rats 
CSF PAF (pg/lOO JLL) 
Treatment 2-Year-old n 16-Week-old n 
Intravenous 
Saline i.v. 9,598±1,974* 9 4,972±935 5 
LPS (1 JLg/kg) 9,840± 1,563* 5 3,820±413 6 
LPS (1.8 mg/kg) 9,047±1,688* 6 2,550±398 6 
Intracerebroventricular 
Saline 7,117±1,164 6 4,735±1,168 4 
LPS (750 ng per rat) 6,096±716 5 4,605±495 4 
LPS (1.35 mg per rat) 22,920±7,359*t 5 5,647±570 6 
Values (mean±SEM) represent platelet activating factor (PAF) levels 2 hours after saline or lipopolysaccharide (LPS) administration. 
n=number of rats. CSF, cerebrospinal fluid. 
·p<0.05 (Tukey's test) compared with 16-week-old rats. 
tp<0.05 (Tukey's test) compared with saline-treated group. 
Statistical analysis by two-way analysis of variance indicated significant difIerences between treatment and age after intracerebroventric-
ular LPS: age (F=7.93350, p=0.00913), treatment (F=5.54648, p=0.01014), interaction agextreatment (F=4.49593, p=0.02099). Corre-
sponding Fand p values after intravenous LPS: age (F=20.36555, p=0.00022), treatment (F=0.49891, p=0.61734), interaction 
agextreatment (F=0.20631, p=0.81489). 
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than did young rats. This species and strain and these 
ages were chosen to correspond to the susceptibilities to 
stroke as previously described.9 The definition of an 
"old" rode nt differs among studies. Most of the studies 
examining the effect of aging on immune function have 
used 24-month-old animals as old test subjectsP-20 
Some studies using 30-36-month-old mice as old sub-
jects conte nd that the age of 24 months actually repre-
sents "middle age" in the rodent life span.21-23 
The effects of aging on cytokine-producing cells are 
complex. In agreement with our present data, serum 
TNF-a activity was increased more than 20-fold in 
30-month-old mice compared with 6-month-old mice 
when the mice were treated with an intravenous injec-
tion of streptococcal endotoxin.24 The isolated murine 
peritoneal macrophages from 24-month-old mice pro-
duced more TNF-a when stimulated with lipopolysac-
charide than did the macrophages from 8-month-old 
mice.21 Macrophages from Lewis rats older than 24 
months had a slightly enhanced production of IL-1 
compared with macrophages from 3-4-month-old 
rats,1? However, peritoneal macrophages from 36-
month-old mice were not significantly different in their 
TNF-a production than 8-month-old mice of the same 
strain.21 Isolated peritoneal macrophages of 12-13-
month-old (middle-aged) and 22-23-month-old (old) 
Fisher rats released less TNF-a than peritoneal macro-
phages of 2-3-month-old rats when challenged with 
Staphylococcus epidermidis. 18 Peritoneal macrophages of 
24-month-old mice also produced less IL-1 than mac-
rophages from 2-4-month-old mice.20 Earlier studies 
have suggested that any impairment in the capacity of 
macrophages to produce cytokines in vitro might be 
compensated for in vivo by the increased number of 
monocytes and macrophages in old animalsp,19 In the 
present study, the monocyte counts in old rats (6±2%) 
were not significantly different than in young rats 
(3± 1 %). Therefore, the increased TNF-a levels in the 
blood and CSF of old animals stimulated with lipopoly-
saccharide may indicate an increased capacity of cells 
from aged rats to produce TNF-a. The studies by 
Shimada24 demonstrating an increased in vivo pro duc-
tion of TNF-a in the serum of old mice support this 
view. Furthermore, the in vivo data may not be directly 
comparable to in vitro studies that used isolated peri-
tone al macrophages because of functional differences 
determined by the tissue from which they were iso la ted 
and the method of isolation.25 
Several Band T lymphocyte functions, such as the 
ability to produce antibodies in response to antigen 
stimulation, mitogen-induced proliferation, and cell-
mediated immune responses, also decrease with ad-
vancing age.1?,22,23,26 The impairment of cell-mediated 
immune reactivity associated with aging seems to be due 
mainly to a defect in the production of IL-2 by helper T 
cells, but the impaired capacity of macrophages to 
produce IL-1 in vitro and the reduced binding of 
cytokines by T cells could also serve as contributing 
factors,18-21,26 It is important to note, however, that the 
phagocytic activity of monocytes and macrophages in 
aged mice and rats is normal. 19,2?-31 The phagocytic 
function of blood monocytes in elderly persons is similar 
to that in young persons.32 Interestingly, phagocytic 
activity, lysosomal acid phosphat ase activity, DNase 
activity, and the synthesis of colony-stimulating factor in 
cultured macrophages were significantly increased in 
17-month-old mice compared with 2-6-month-old, or 
young, mice.33 The age-dependent increase in macro-
phage activity is particularly pronounced in New 
Zealand black mice, which exhibit progressively de-
pressed cellular immunity.33 Interestingly, impaired 
T -cell function is also associated with hypertension, a 
known risk factor for stroke.34 Moreover, the number of 
activated monocytes is significantly elevated in mature 
hypertensive rats compared with normotensive rats,11,35 
Thus, it is possible that the decreased cellular immunity 
in aging and hypertension is compensated for by an 
increase in the number and activity of macrophages, as 
reported in athymic nude mice.36 
The exaggerated production of TNF-a in vivo has 
been demonstrated in spontaneously hypertensive 
rats,1°,l1 Expression of RNA message for monocyte 
chemoattractant protein-1 and immunoreactive TNF-a 
has also been detected in human atherosclerotic le-
sions.3-5 Our recent studies demonstrated increased 
expression of the intercellular adhesion molecule 
(ICAM)-1, increased accumulation of macrophages, 
and increased in vitro production of TNF-a by carotid 
arte ries of hypertensive rats.3? Preliminary studies dem-
onstrated enhanced in vitro production of TNF-a in 
carotid arteries obtained from aged Sprague-Dawley 
rats. The aged rats have also been reported to exhibit an 
increased reactivity to TNF-a or IL-1 in that the 
cytokine-induced increase in the plasma levels of plas-
minogen activator inhibitor activity in aged rats was 
greater than in young rats.38 
According to our working hypo thesis, the relevance of 
the increased cytokine release to stroke lies in the 
ability of cytokines such as TNF-a to prepare vessels for 
ischemic and inftammatory tissue damage through in-
creased adhesion of leukocytes and platelets on vascular 
endothelium and transformation of the endothelial sur-
face from an actively anticoagulant to a procoagulant 
state. Some of the specific endothelial changes under 
the inftuence of TNF-a include the synthesis and sur-
face expression of tissue factor,6 the synthesis and 
expression of PAF,6 the release of IL-1,6 the release of 
factor VIII,6 and the enhanced adhesion of monocytes 
and granulocytes6-8 through the expression of adhesion 
receptor molecules.6- 8 In addition, TNF-a can inhibit 
anticoagulant mechanisms such as the thrombomodu-
lin-protein C-protein S system and decrease fibrinolysis 
as the levels of plasminogen activator inhibitor are 
increased.6 The overall effect of these interactions is to 
ren der the endothelial cell surface procoagulant, in-
crease the adhesion of platelets and leukocytes, and 
increase local permeability. Our working hypothesis 
thus suggests that an interaction between perivascular 
macrophages and endothelium through cytokines could 
contribute to an increased risk of stroke in advanced 
age. We believe that our findings could be potentially 
relevant to human stroke in that the alte red state of 
blood vessels induced by stroke risk factors could render 
such vessels locally vulnerable to thrombosis or hemor-
rhage in response to transient activation of intravascular 
coagulation or of complement by any of a wide variety 
of mechanisms (factors such as natural oscillation of 
coagulation potential, stress, infection, trauma, and 
inftammation). The site of thrombus formation would 
be determined by the preexisting vessel disturbance and 
not by the intravascular process activating the comple-
ment or coagulation systems, thereby following the local 
Shwartzman reaction paradigm.6 - S In this view, stroke 
would develop as the focal consequence of disturbed 
regulation of systems mediating coagulation, inftamma-
tion, and immunity, which are normally required for 
preservation of the integrity of the organism. Increased 
risk for a thromboembolic stroke could be possible if 
this process were to take place mainly in the extracra-
nial vessels supplying the brain, whereas changes occur-
ring in the intraparenchymal microvessels could contrib-
ute to lacunar strokes. Although our present data seem 
to support thc working hypothesis, it should be empha-
sized that the true relevance of our findings to human 
stroke can be assessed only in forthcoming clinical 
studies that examine the role of the cytokine system in 
stroke patients and individuals with stroke risk factors. 
The levels of TNF-a in the CSF were greater after the 
intracerebroventricular injection of lipopolysaccharide 
than after its systemic administration, indicating a local 
production of TNF-a within the central nervous system. 
These findings agree with earlier studies, which showed 
that the TNF-a activity was greater in the CSF than in 
blood after the intracerebroventricular injection of lipo-
polysaccharide in hypertensive rats.1o. l1 The perivascu-
lar macrophages derived from bone marrow39 could 
account for the production of TNF-a in the brain, 
because monocytes and macrophages are a major source 
for TNF-a.6•13 However, several other cell types in the 
central nervous system are capable of TNF-a expres-
sion. The ameboid microglia share many features with 
macrophages, including the production of IL-1 and 
TNF-a.40 Astrocytes mayaiso be capable of transform-
ing into macrophage-like cells41 and have been shown to 
release cytokines in vitro.40 Furthermore, macrophages 
within ependyma and meninges could also contribute to 
the TNF-arelease into the CSF. In a previous study, we 
found that lipopolysaccharide induced a concentration-
dependent TNF-a release in isolated rat brain slices.37 
The level of TNF-a reached 3,OOO±263 units/mg pro-
tein per hour after incubation with lipopolysaccharide 
(1 mg/mL). Because the meninges were routinely re-
moved before slices were prepared for incubation, a 
predominant contribution by meningeal macrophages to 
the TNF-a release in the brain slices seems unlikely. In 
arecent study, TNF-a mRNA has been reported to be 
expressed in the normal mouse brain, but the effect of 
lipopolysaccharide was not tested.42 Surprisingly, the 
predominant cells expressing TNF-a mRNA in the 
mouse brain were neurons, although expression was 
also seen in ependymal cells and, to a lesser degree, in 
microglia.42 However, the TNF-a message in the brain 
cells was not translated to the protein product because 
the cells positive for TNF-a mRNA did not contain 
detectable levels of immunoreactive TNF-a.42 Thus, the 
relative contribution of the various cell types to the 
release of TNF-a into CSF in intact animals will not be 
clarified until studies using in situ hybridization and 
immunohistochemistry to reveal the exact cell types 
expressing mRNA for TNF-a after lipopolysaccharide 
stimulation in vivo become available. The TNF-a re-
leased into the CSF could contribute to the ischemic 
and hemorrhagic lesions found in the brain stern of aged 
rats after a provocative dose of lipopolysaccharide.9 
This inference is supported by the recent finding of 
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hemorrhagic necrosis of the neuropil after the adminis-
tration of recombinant TNF-a into the central nervous 
system.43 
The present study also demonstrated an exaggerated 
release of an immediate proinftammatory media tor in 
the brains of aged animals, as evidenced by the increase 
of PAF in the CSF after the intracerebroventricular 
administration of provocative doses of lipopolysaccha-
ride. P AF is a lipid media tor that induces platelet 
aggregation, increases vascular permeability, and acts as 
an endothelial adhesion receptor for white blood cells.12 
P AF in the CSF could originate from multiple cell 
types, including the endothelial cells, monocytes and 
macrophages, neutrophils, glial cells, and neurons.44- 46 
However, the mononuclear cells have been proposed as 
the primary source for P AF in responses to lipopolysac-
charideY Interestingly, TNF-a can induce PAF release 
from endothelial cultures.44 This finding may be ar rele-
vance to our results, because the high levels of P AF and 
TNF-a found in the CSF after lipopolysaccharide ad-
ministration were temporally related. 
In conclusion, the present study provides support for 
our working hypothesis that advanced age, a risk factor 
for stroke, creates astate of increased probability of an 
interaction between monocytes/macrophages and endo-
thelial cells, thereby enhancing local thrombosis or 
hemorrhage through increased activity of cytokines. 
According to this hypothesis, risk factors for stroke are 
initially associated with a change in endothelium and a 
hyperactive state of the monocytes/macrophages. The 
endothelial change would probably involve the expres-
sion of endothelial adhesion receptors for monocytes, 
which in turn would facilitate the adherence of mono-
cytes to the vessel wall and transendothelial migration 
in both large and small vessels, leading to local deposits 
of monocyte clusters in segments of the blood vessels. 
These monocyte clusters could then periodically signal 
the vessel endothelium through the release of pro-
thrombotic, proinftammatory, and chemotactic media-
tors such as TNF-a, PAF, and, perhaps, IL-1 to convert. 
the endothelium to a procoagulant state and, in effect, 
prepare those vessel segments in a manner similar to the 
localized Shwartzman paradigm. Complement activa-
tion or any stimulus leading to activation of the coagu-
lation system (factors such as natural oscillation of 
coagulation potential, stress, infection, trauma, and 
inftammation) could then precipitate a localized reac-
tion within this prepared vessel segment and lead to a 
local thrombosis or hemorrhage. Because we have cho-
sen to test this hypothesis first in an animal model, the 
conclusions of this study at this point are restricted to 
the species used. However, many aspects of this work 
can be tested in humans, and it remains for these future 
studies to show whether the proposed mechanisms are 
operating in clinical stroke. 
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